Sylics was acquired by InnoSer. To see what’s new, read below or use the navigation bar to find the information you need.

    Duchenne Muscular Dystrophy (DMD) Mouse Model

    Perform behavioural research studies to investigate your novel and innovative targeted Duchenne Muscular Dystrophy therapies using the mdx mouse model

    Home » Neurology CRO Services » Neuromuscular Disease – Duchenne Muscular Dystrophy (mdx)

    Duchenne muscular dystrophy (DMD) is a neuromuscular disorder characterized by progressive skeletal muscle weakening and wasting. To test the efficacy of novel therapies or disease-modifying treatments for DMD, multiple research models can be used. Out of these, the most commonly used is the mdx (B10. mdx) mouse model. The mdx mouse model closely recapitulates the human DMD pathophysiological characteristics due to an X-linked mutation in the gene that encodes dystrophin in the skeletal muscle membrane. 

    Mdx mice show progressive cycles of skeletal muscle degeneration and regeneration that mimic human course of DMD, starting at approximately three weeks of age. As part of its preclinical research services, InnoSer performs efficacy studies in the mdx mouse model, focusing on functional readouts (skeletal muscle strength, motor function) as well as histopathology analyses (e.g., WGA, Sirius red, H&E) of skeletal muscle (regeneration, necrosis, hypertrophy). 

    Take advantage of InnoSer’s expertise, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with performing preclinical behavioural research services in in vivo models and help guide your decision on choosing the best model fit for your current research goals. 

    InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies). 

    Mdx mouse key model characteristics:

    • The mdx mutation results in a termination codon of the dystrophin muscular dystrophy (Dmd) gene on the X chromosome.
    • Mdx mice show robust muscle function impairments at a young age and display cognitive impairments under specific conditions (Remmelink et al. 2016; Engelbeen et al. 2021). 

    Find the right model for you.

    Compare our model capabilities and discover which of our neurology platforms suits your research needs

    Belgian based preclinical neurology CRO mouse models

    Key readouts in the DMD mouse model

    Test the efficacy of your treatments with the following commonly used behavioral tests:

    Motor function:

    Assess the efficacy of your treatments with the following biological readouts:

    • Histopathology (e.g., WGA, Sirius red, H&E etc.,) of skeletal muscle (regeneration, necrosis, hypertrophy) and heart tissue.

    Example data featuring the DMD mouse model: 

    Related neuromuscular disease model options

    Neurology Platform Overview

    Highly relevant neurology models to facilitate preclinical drug development.

    Charcot Marie Tooth Disease Type 1A C3-PMP22 Mouse Model

    InnoSer offers a fee-for-service C-3PMP22 model to research novel therapies against Charcot Marie Tooth Type 1A. 

    Spasticity – Spa Mouse Model

    Study novel interventions to improve physical performance in patients affected by muscular Spasticity using the Spa mouse model.  

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Ready to work with a CRO that’s as committed as you are?

     

    Join us in delivering impactful studies that bring therapies to patients sooner.